8-K: Avantor Appoints Life Sciences Veteran Gregory Lucier to Board

Avantor, Inc. has appointed Gregory T. Lucier, a seasoned executive with over 30 years of experience in the life sciences and advanced technology industries, to its Board of Directors, effective October 3, 2025.

Summary

• Avantor, Inc. elected Gregory Lucier as a director to its Board of Directors, effective October 3, 2025.
• Mr. Lucier's initial term will expire on the date of the company's 2026 Annual Meeting of Stockholders.
• He currently serves as Executive Chairman and Chief Executive Officer of Corza Medical, a surgical technologies company, since 2021.
• His prior roles include Chairman and CEO of NuVasive, Inc. (2015-2021) and Chairman and CEO of Life Technologies (2003-2014), where he grew Invitrogen to over $4 billion in sales and oversaw its sale to Thermo Fisher Scientific.
• Mr. Lucier also held corporate officer and executive leadership roles at General Electric Company.
• He currently serves on the board of directors of Maravai Lifesciences Holdings, Inc. and as non-executive chairman of the board of Dentsply Sirona, Inc.
• Mr. Lucier holds an MBA from Harvard Business School and a bachelor's degree in industrial engineering from Pennsylvania State University.
• The Board determined Mr. Lucier meets all applicable independence standards of the New York Stock Exchange and the Securities Exchange Act of 1934.
• He will receive standard non-employee director compensation, including an annual cash retainer of $95,000 (prorated for 2025) and a grant of restricted stock units with a grant date fair value of $210,000 (prorated), vesting one year from the grant date.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced and well-regarded industry veteran to the Board of Directors is a positive development for corporate governance and strategic guidance, indicating a commitment to strengthening leadership.

Positives

• The appointment of Gregory Lucier brings over three decades of leadership experience and a strong track record of driving growth and innovation in the life sciences sector.
• Mr. Lucier's extensive background, including CEO roles at Corza Medical, NuVasive, and Life Technologies, aligns well with Avantor's strategic focus on life sciences and advanced technology industries.
• His current and past board memberships, including Maravai Lifesciences and Dentsply Sirona, demonstrate broad governance experience.
• The Board has determined Mr. Lucier meets all applicable independence standards, enhancing corporate governance.

Risks

• The press release contains forward-looking statements that are inherently subject to risks, uncertainties, and assumptions, and are not guarantees of performance.
• Factors that could contribute to these risks, uncertainties, and assumptions are described in the company's most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Future Outlook

The company's forward-looking statements discuss current expectations and projections relating to financial condition, results of operations, plans, objectives, future performance, and business, including a cost transformation initiative. These statements are subject to inherent risks, uncertainties, and assumptions, and are not guarantees of performance. The company does not undertake obligations to update or revise any forward-looking statements unless required by federal securities laws.

Management Comments

• Jonathan Peacock, Chairman of the Avantor Board, stated: "We are excited to welcome Greg to the Avantor Board of Directors. Greg has a tremendous track record of driving growth and innovation during his more than 30-year career in the Life Sciences sector. We look forward to benefitting from the invaluable perspectives he brings to our Board as the Company focuses on unlocking Avantor's potential and delivering sustainable shareholder value by driving growth and profitability across the Lab Solutions and Bioscience Production segments."
• Gregory Lucier commented: "Avantor has the right foundation in place for sustained industry leadership and long-term value creation. Throughout my career, I have enjoyed working closely with teams of talented executives to capitalize on growth opportunities in the healthcare market. I look forward to partnering with Avantor's Board and management team to further strengthen the Company's platform and advance its mission."

Industry Context

The appointment of Gregory Lucier, with his extensive background in life sciences, surgical technologies, and medical devices, reinforces Avantor's strategic focus on being a leading global provider of mission-critical products and services to the life sciences and advanced technology industries. His experience at companies like Life Technologies and NuVasive positions him to contribute to Avantor's growth and innovation in a competitive and evolving healthcare market.

Management Changes

Corporate Governance

Related Party Transactions

• There are no arrangements or understandings with any other persons pursuant to which Mr. Lucier was selected as a director, and he does not have a direct or indirect material interest in any current or proposed transaction requiring disclosure under Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders: Expected to benefit from enhanced strategic guidance and oversight due to the addition of an experienced industry leader to the Board.
• Management: Will gain from Mr. Lucier's extensive experience in driving growth and innovation within the life sciences sector.

Next Steps

• Gregory Lucier's initial term as a director will expire on the date of the company's 2026 Annual Meeting of Stockholders.

Key Dates

Keywords

Avantor, AVTR, Board of Directors, Gregory Lucier, Life Sciences, Advanced Technology, Corporate Governance, Director Appointment, Biotechnology, Medical Devices